iohexol has been researched along with alpha-Galactosidase A Deficiency in 1 studies
Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.
iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wijburg, FA | 1 |
| Bénichou, B | 1 |
| Bichet, DG | 1 |
| Clarke, LA | 1 |
| Dostalova, G | 1 |
| Fainboim, A | 1 |
| Fellgiebel, A | 1 |
| Forcelini, C | 1 |
| An Haack, K | 1 |
| Hopkin, RJ | 1 |
| Mauer, M | 1 |
| Najafian, B | 1 |
| Scott, CR | 1 |
| Shankar, SP | 1 |
| Thurberg, BL | 1 |
| Tøndel, C | 1 |
| Tylki-Szymańska, A | 1 |
| Ramaswami, U | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Podocyturia, a Non-Invasive Predictor of Renal Dysfunction in Fabry Nephropathy[NCT02994303] | 58 participants (Anticipated) | Observational | 2014-09-30 | Recruiting | |||
| A Randomized, Multicenter, Multinational, Phase 3B, Open-Label, Parallel-Group Study of Fabrazyme (Agalsidase Beta) in Treatment-Naïve Male Pediatric Patients With Fabry Disease Without Severe Symptoms[NCT00701415] | Phase 3 | 31 participants (Actual) | Interventional | 2008-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Plasma samples were assayed for GL-3 clearance using a validated tandem mass spectrometry with an upper limit of normal plasma GL-3 level of 7.0 μg/mL. Number of participants analyzed=participants with both baseline and post-baseline GL-3 plasma clearance assessment. Here 'n' signifies number of participants with available data for specified category. (NCT00701415)
Timeframe: Baseline, Week 12, 28, 40, 52, 80, 104, 132, 156, 184, 208, 236 and 260
| Intervention | Percent change (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 12 (n=14, 11) | Week 28 (n=14, 14) | Week 40 (n=13, 14) | Week 52 (n=14, 14) | Week 80 (n=13, 14) | Week 104 (n=13, 14) | Week 132 (n=11, 14) | Week 156 (n=11, 14) | Week 184 (n=12, 14) | Week 208 (n=12, 14) | Week 236 (n=12, 14) | Week 260 (n=11, 14) | |
| Fabrazyme 0.5 mg/kg | -52.37 | -49.06 | -52.01 | -52.29 | -52.91 | -51.08 | -61.39 | -48.72 | -53.62 | -48.83 | -56.44 | -59.95 |
| Fabrazyme 1.0 mg/kg | -52.74 | -47.55 | -50.82 | -45.87 | -48.93 | -39.92 | -52.97 | -44.83 | -49.08 | -46.09 | -47.25 | -46.34 |
Plasma samples were assayed for total urine GL-3 clearance using a validated tandem mass spectrometry with an upper limit of normal of <0.030 mg/mmoL of creatinine. Number of participants analyzed=participants with both baseline and post-baseline GL-3 urine clearance assessment. Here 'n' signifies number of participants with available data for specified category. (NCT00701415)
Timeframe: Baseline, Week 12, 28, 40, 52, 80, 104, 132, 156, 184, 208, 236 and 260
| Intervention | Percent change (Mean) | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Week 12 (n=15, 14) | Week 28 (n=15, 15) | Week 40 (n=15, 14) | Week 52 (n=15, 14) | Week 80 (n=14, 14) | Week 104 (n=14, 14) | Week 132 (n=13, 14) | Week 156 (n=13, 14) | Week 184 (n=13, 14) | Week 208 (n=13, 14) | Week 236 (n=13, 14) | Week 260 (n=13, 14) | |
| Fabrazyme 0.5 mg/kg | -50.77 | -50.84 | -44.22 | -70.1 | -35.84 | -21.92 | -48.79 | -65.57 | -76.54 | -60.94 | -69.08 | -57.59 |
| Fabrazyme 1.0 mg/kg | -63.39 | -52.55 | -63.87 | -20.72 | 35.22 | -56.39 | -45.61 | -28.92 | -10.5 | -50.93 | -40.09 | -28.27 |
Skin biopsies were taken at Baseline, Week 52, Week 156 and Week 260 or early withdrawal and analyzed for cellular GL-3 accumulation (inclusions) by light microscopy. Each biopsy was scored for GL-3 accumulation on a severity score-scale of none, mild, moderate, severe (0-1-2-3). Scores are categorized as normal (score = 0) or abnormal (score = 1, 2 or 3). Data was summarized in terms of number of participants with none/trace, mild, moderate and severe biopsy scores. (NCT00701415)
Timeframe: Baseline, Week 52, Week 156 and Week 260
| Intervention | Percentage of participants (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Zero (0) Skin GL-3 Score at Baseline | Zero (0) Skin GL-3 Score at Week 52 | Zero (0) Skin GL-3 Score at Week 156 | Zero (0) Skin GL-3 Score at Week 260 | Mild (1) Skin GL-3 Score at Baseline | Mild (1) Skin GL-3 Score at Week 52 | Mild (1) Skin GL-3 Score at Week 156 | Mild (1) Skin GL-3 Score at Week 260 | Moderate (2) Skin GL-3 Score at Baseline | Moderate (2) Skin GL-3 Score at Week 52 | Moderate (2) Skin GL-3 Score at Week 156 | Moderate (2) Skin GL-3 Score at Week 260 | Severe (3) Skin GL-3 Score at Baseline | Severe (3) Skin GL-3 Score at Week 52 | Severe (3) Skin GL-3 Score at Week 156 | Severe (3) Skin GL-3 Score at Week 260 | Missing Skin GL-3 Score at Baseline | Missing Skin GL-3 Score at Week 52 | Missing Skin GL-3 Score at Week 156 | Missing Skin GL-3 Score at Week 260 | |
| Fabrazyme 0.5 mg/kg | 18.8 | 75 | 56.3 | 68.8 | 6.3 | 6.3 | 18.8 | 12.5 | 75 | 0 | 6.3 | 0 | 0 | 0 | 0 | 0 | 0 | 18.8 | 18.8 | 18.8 |
| Fabrazyme 1.0 mg/kg | 33.3 | 80 | 80 | 66.7 | 0 | 13.3 | 0 | 20 | 66.7 | 0 | 13.3 | 6.7 | 0 | 0 | 0 | 0 | 0 | 6.7 | 6.7 | 6.7 |
1 trial available for iohexol and alpha-Galactosidase A Deficiency
| Article | Year |
|---|---|
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
Topics: Adolescent; Biopsy; Brain; Child; Child, Preschool; Demography; Endothelium, Vascular; Fabry Disease | 2015 |
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
Topics: Adolescent; Biopsy; Brain; Child; Child, Preschool; Demography; Endothelium, Vascular; Fabry Disease | 2015 |
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
Topics: Adolescent; Biopsy; Brain; Child; Child, Preschool; Demography; Endothelium, Vascular; Fabry Disease | 2015 |
Characterization of early disease status in treatment-naive male paediatric patients with Fabry disease enrolled in a randomized clinical trial.
Topics: Adolescent; Biopsy; Brain; Child; Child, Preschool; Demography; Endothelium, Vascular; Fabry Disease | 2015 |